PEspeaks

Sep 04, 2015
The use of real-time data (RTD) in clinical studies offers several advantages for those sponsors armed with the resources to effectively manage and analyze the constant flow of incoming data.
Sep 04, 2015
The clocks are ticking for Express Scripts, writes Stephen E. Littlejohn. Having achieved formidable “size and scale,” how will the nation’s largest pharmacy benefit manager synchronize with value-based health care?
Sep 03, 2015
As the U.S. Open Payments system improves operations and resolves discrepancies, the emergence of widely diverse and contradictory transparency programs in Europe and other nations raises new challenges for pharma, writes Jill Wechsler.
Aug 28, 2015
The latest organization to join the cost-effectiveness stampede is the NCCN, which recently announced that it would add a new “tool” to its widely used guidelines that advise oncologists on cancer treatment strategies.
Aug 27, 2015
France's bid to regain its influence reveals how far Europe is from fully achieving regulatory convergence, writes Reflector.
Aug 26, 2015
A recent poll reported that most Americans think drug prices are unreasonably high, but that 76% of Republicans prefer market competition over government regulation to lower prices. Stephen Littlejohn imagines what Donald Trump would say on the matter.
Aug 13, 2015
FDA needs to expand and empower its Office of Health & Constituent Affairs and its Patient Liaison Program to better coordinate interactions with individuals and physicians seeking expedited access to experimental therapies, writes Jill Wechsler.
Aug 13, 2015
Pharmaceutical Executive
The big data revolution offers great promise for drug development versus the traditional ways of bringing medicines to market, but there is a larger issue at stake: how to turn data quantity into data quality. William Looney reports.
Aug 06, 2015
As was the case decades ago, the “drug line” continues to be a major, if not the primary, concern of Medicaid administrators across the nation.
Aug 05, 2015
Pharmaceutical Executive
Despite overwhelming House approval last month of the 21st Century Cures Act, bipartisan support may fall apart in the coming months, writes Jill Wechsler.